Resultados de Búsqueda

Evidencias COVID-19

Oxford COVID-19 Evidence Service

There have been no reports of the results of well-designed clinical trials of the use of azithromycin in COVID-19. It is more likely to reduce the risk of secondary bacterial infection than to have a direct antiviral effect, but other antibacterial agents are preferable for this purpose. It should not be used in combination with hydroxychloroquine. Until the results of adequately powered, double-masked, randomized controlled trials appear, if any, it should not be used to treat COVID-19 except ...

Evidencias COVID-19

Oxford COVID-19 Evidence Service

There have been no studies examining the use of mast cell stabilisers, leukotriene antagonists or anti-histamines in COVID-19. Lung damage and “cytokine storm” observed in SARS-CoV-2 infection are associated with raised pro-inflammatory cytokines. Mast cells are the main source of these. It has been speculated that mast cell stabilisers may attenuate pulmonary complications, fatal inflammation and death in COVID-19. It is unclear whether administration of mast cell stabilisers in COVID-19 ...

Evidencias COVID-19

Oxford COVID-19 Evidence Service

Management of delirium in Covid-19 is particularly challenging where availability of PPE and access to remote consultation technology is likely to be severely restricted. Poorly developed mental health services and lack of training of health care professionals in management of psychiatric conditions including delirium will further compound this. The principles of management outlined in this review should be followed as far as possible but pharmacological management may be required early. ...

Evidencias COVID-19

Oxford COVID-19 Evidence Service

There are no validated tests for assessing breathlessness over the phone in an acute primary care setting. Measuring a patient’s respiratory rate over the phone using the Roth Score does not provide an accurate assessment of hypoxia and may lead to false reassurance. Experts recommend an overall clinical assessment, including questions about the nature and rate of change of the breathlessness.

Evidencias COVID-19

Oxford COVID-19 Evidence Service

During the current COVID-19 pandemic, the possible benefits of providing prescriptions for 3 months’ duration, as opposed to shorter durations, may include: reducing person to person contact in order to slow transmission rates, reducing anxiety among patients with long-term conditions who require repeat prescriptions, reducing health services burden and costs. However, during a global pandemic it is possible that interruptions in manufacturing and other activities may exacerbate medicines ...